Skip to main content
SpringerLink
Log in

Postoperative Endocrine Therapy for Invasive Breast Cancer

  • Chapter
  • First Online:
Adjuvant Therapy for Breast Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 151))

Estrogen plays a key role in mammary carcinogenesis, identifying the pathways that regulate estrogen function as major targets for breast cancer therapy. Expression of the estrogen receptor α (ERα) or the progesterone receptor (PR) is a widely recognized predictor of response to hormonal therapy [1]. Studies of endocrine manipulation conducted in advanced breast cancer have revealed response rates of 80% for ER+/PR+ tumors, 40–45% for ER–/PR+ tumors, 25–30% for ER+/PR– tumors, and less than 10% for ER–/PR– tumors. More recently, data have demonstrated that over-expression of ER or PR in at least 1% of breast tumor cells indicates potential responsiveness to endocrine therapy [2, 3]. In the absence of ER or PR expression, endocrine therapy is not indicated. These observations highlight the importance of an accurate measurement of ER and PR expression in the primary tumor in therapeutic decision-making. Currently, quality-controlled quantitative immunohistochemistry is the method of choice [4, 5].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46(12 Suppl):2884–8.

    Article  PubMed  CAS  Google Scholar 

  2. Harvey J, Clark G, Osborne C, Allred D. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.

    PubMed  CAS  Google Scholar 

  3. Mohsin S, Wiess H, Gutierrez M, et al. Neoadjuvant Trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005;23:2460–8.

    Article  PubMed  CAS  Google Scholar 

  4. Goldhirsch A, Wood W, Gelber R, et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357–65.

    Article  PubMed  Google Scholar 

  5. Zafrani B, Aubriot H, Mouret E, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: Comparison with biochemical determination in a prospective study of 793 cases. Histopathol. 2000;37:536–45.

    Article  CAS  Google Scholar 

  6. Clarke M. Ovarian ablation in breast cancer, 1896–1998: Milestones along hierarchy of evidence from case report to Cochrane review. BM J. 1998;317:1246–8.

    Article  CAS  Google Scholar 

  7. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431–42.

    Article  PubMed  CAS  Google Scholar 

  8. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol. 2000;18(17):3172–86.

    PubMed  CAS  Google Scholar 

  9. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A. 1992;89(9):4037–41.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet. 2005;365:1687–717.

    Article  CAS  Google Scholar 

  11. Perou C, Sorlie T, Eisen M, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747–52.

    Article  PubMed  CAS  Google Scholar 

  12. Sorlie T, Perou C, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Dowsett M, Harper-Wynne C, Beoddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001;61:8452–8.

    PubMed  CAS  Google Scholar 

  15. Moy B, Goss P. Estrogen receptor pathways: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res. 2006;15:4790–3.

    Article  Google Scholar 

  16. Choi J, Nowell S, Blanco J, Ambrosone C. The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 2006;7:613–24.

    Article  PubMed  CAS  Google Scholar 

  17. Wiebe V, Osborne C, Fuqua S, DeGregorio M. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol. 1993;14:173–88.

    Article  PubMed  CAS  Google Scholar 

  18. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: Update 2006. CA Cancer J for Clinicians. 2006;56:168–83.

    Article  Google Scholar 

  19. Pujol P, Daures J, Thezenas S, et al. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer. 1998;83:698–705.

    Article  PubMed  CAS  Google Scholar 

  20. Goldhirsch A, Glick J, Gelber R, et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol. 2001;19(18):3817–27.

    PubMed  CAS  Google Scholar 

  21. Prowell T, Davidson N. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist. 2004;9:507–17.

    Article  PubMed  Google Scholar 

  22. Goldhirsch A, Glick J, Gelber R, et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Annals Oncol. 2005;16:1569–83.

    Article  CAS  Google Scholar 

  23. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-related, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

    Article  PubMed  CAS  Google Scholar 

  24. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen-receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.

    Article  PubMed  CAS  Google Scholar 

  25. Early Breast Cancer Clinical Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: Overview of the randomized trials. Lancet. 1998;351:1451–67.

    Article  Google Scholar 

  26. Nolvadex Adjuvant Trial Organization (NATO). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer. 1988;57:608–11.

    Article  Google Scholar 

  27. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–84.

    Article  PubMed  CAS  Google Scholar 

  28. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–90.

    Article  PubMed  CAS  Google Scholar 

  29. Stewart H. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. J Natl Cancer Inst. 1992;11:117–20.

    Google Scholar 

  30. Stewart H, Forrest A, Everington D, et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet. 1996;348:708–13.

    Article  PubMed  Google Scholar 

  31. Stewart H, Prescott R, Forrest A. Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years. J Natl Cancer Inst. 2001;93:456–62.

    Article  PubMed  CAS  Google Scholar 

  32. Boccardo F, Amoroso D, Rubagotti A, et al. Endocrine therapy of breast cancer: The experience of the Italian cooperative group for chemohormonal therapy of early breast cancer. Annals New York Acad Sci. 1993;698:318–29.

    Article  CAS  Google Scholar 

  33. Kaufmann M, Jonat W, Abel U, et al. Adjuvant randomized trials of doxorubicin/cyclo-phosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol. 1993;11:454–60.

    PubMed  CAS  Google Scholar 

  34. Tormey DC, Gray R, Abeloff MD, et al. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol. 1992;10:1848–56.

    PubMed  CAS  Google Scholar 

  35. Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006;24:1332–41.

    Article  PubMed  CAS  Google Scholar 

  36. Beatson G. On the treatment of inoperable cases of carcinoma of the mamm: Suggestions for new method of treatment. Lancet. 1896;2:104–7.

    Article  Google Scholar 

  37. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet. 1996;348:1189–96.

    Article  Google Scholar 

  38. Scottish Cancer Trials Breast Group and ICRF, Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet. 1993;341:1293–8.

    Google Scholar 

  39. Ejlertsen B, Mouridsen H, Jensen M, et al. Similar efficacy for ovarian ablation compared with cylcophosphamide, methotrexate, and fluorouracil: From a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol. 2006;24:4956–62.

    Article  PubMed  CAS  Google Scholar 

  40. Schmid P, Untch M, Wallwiener D, et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res. 2002;22:2325–32.

    PubMed  CAS  Google Scholar 

  41. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association study. J Clin Oncol. 2002;20:4628–35.

    Article  PubMed  CAS  Google Scholar 

  42. Petrek J, Naughton M, Case L, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol. 2006;24:1045–51.

    Article  PubMed  Google Scholar 

  43. Goldhirsch A, Gelber R, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001;30:44–51.

    Article  PubMed  Google Scholar 

  44. Davidson N, O'Neill A, Vukov A, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT0101 (E5188). J Clin Oncol. 2005;23:5973–82.

    Article  PubMed  CAS  Google Scholar 

  45. Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer. 2006;42:895–904.

    Article  PubMed  CAS  Google Scholar 

  46. International Breast Cancer Research Study Group. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–93. Breast. 2001;10:130–8.

    Google Scholar 

  47. Castiglione-Gertsch M, O'Neill A, Price K, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst. 2003;95:1833–46.

    Article  PubMed  CAS  Google Scholar 

  48. Arriagada R, Le M, Spielmann M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjvuant chemotherapy. Annals Oncol. 2005;16:389–96.

    Article  CAS  Google Scholar 

  49. Robert N, Wang M, Wood W. Phase III comparison of tamoxifen with ovarian ablation in premenopausal women with axillary node-negative, receptor-positive breast cancer <3 cm. Proc Am Soc Clin Oncol. 2003;22:16a.

    Google Scholar 

  50. Love R, Duc N, Allred D, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002;20:2559–66.

    Article  PubMed  Google Scholar 

  51. Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol. 2000;18:2718–27.

    PubMed  CAS  Google Scholar 

  52. Roche H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Annals Oncol. 2006;17:1221–7.

    Article  CAS  Google Scholar 

  53. Roche H, Mihura J, de Lafontan B, et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node- and receptor-positive breast cancer patients: A randomized trial with a 7 years median follow up. Proc Am Soc Clin Oncol. 1996;15:117.

    Google Scholar 

  54. The Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: Results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. J Natl Cancer Inst. 2007;99:516–25.

    Article  PubMed  Google Scholar 

  55. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer–Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002;20:4621–7.

    Article  PubMed  CAS  Google Scholar 

  56. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomized adjuvant trials. Lancet. 2007;369:1711–23.

    Article  CAS  Google Scholar 

  57. Paik S. Molecular profiling of breast cancer. Curr Opin Obst Gynecol. 2006;18:59–62.

    Article  Google Scholar 

  58. Kennecke H, Olivotto I, Speers C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Annals Oncol. 2007;18:45–51.

    Article  CAS  Google Scholar 

  59. Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr. 2001;30:56–61.

    Article  PubMed  Google Scholar 

  60. Baum M, Budzar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet. 2002;359:2131–9.

    Article  PubMed  CAS  Google Scholar 

  61. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–2.

    Article  PubMed  CAS  Google Scholar 

  62. Thurlimann B, Keshaviah A, Coates AS, et al. Breast International Group (BIG) 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–57.

    Article  PubMed  Google Scholar 

  63. Coates A, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol. 2007;25:486–92.

    Article  PubMed  CAS  Google Scholar 

  64. Ryan P, Goss P. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. The Oncologist. 2006;11: 718–31.

    Article  PubMed  CAS  Google Scholar 

  65. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23:5138–47.

    Article  CAS  Google Scholar 

  66. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–62.

    Article  PubMed  CAS  Google Scholar 

  67. Kaufmann M, Jonat W, Hilfrich H, et al. Survival benefit of switching to anastrozole after 2 years of treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study (abstract 547). J Clin Oncol. 2006;24(18S):14s.

    Google Scholar 

  68. Coombes R, Hall E, Gibson L, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.

    Article  PubMed  CAS  Google Scholar 

  69. Coombes R, Kilburn L, Snowdon C, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet. 2007;369:559–70.

    Article  PubMed  CAS  Google Scholar 

  70. Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–802.

    Article  PubMed  CAS  Google Scholar 

  71. Goss P, Ingle J, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–71.

    Article  PubMed  CAS  Google Scholar 

  72. Robert N, Goss P, Ingle J, et al.. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding (abstract 550). Proc Am Soc Clin Oncol. 2006;24(18s):5s.

    Google Scholar 

  73. Goss P, Ingle J, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007;25:2006–11.

    Article  PubMed  CAS  Google Scholar 

  74. Ingle J, Tu D, Pater J, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. 2006;99:295–300.

    Article  PubMed  CAS  Google Scholar 

  75. Jakesz R, Samonigg R, Greil M, et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc Am Soc Clin Oncol. 2005;23(16s):10s.

    Google Scholar 

  76. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis. Lancet Oncol. 2006;7:991–6.

    Article  PubMed  CAS  Google Scholar 

  77. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on bone mineral density and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Mineral Res. 2006;21:1215–23.

    Article  CAS  Google Scholar 

  78. Coleman R, Banks L, Girgis S, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol. 2007;8:119–27.

    Article  PubMed  CAS  Google Scholar 

  79. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–35.

    Article  PubMed  CAS  Google Scholar 

  80. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr. 2001;30:5–15.

    Google Scholar 

  81. Winer E, Hudis C, Burstein H, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol. 2005;23:619–29.

    Article  PubMed  CAS  Google Scholar 

  82. Smith I, Dowsett M, Yap Y, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines. J Clin Oncol. 2006;24:2444–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, USA

    Leisha A. Emens MD, PhD

  2. University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    Nancy E. Davidson MD

Authors
  1. Leisha A. Emens MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy E. Davidson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leisha A. Emens MD, PhD .

Editor information

Editors and Affiliations

  1. Inselspital, Univ. Bern, Bern, 3010, Switzerland

    Monica Castiglione

  2. Inst. Jules Bordet, Universite Libre Bruxelles, Bd. de Waterloo 125, Bruxelles, 1000, Belgium

    Martine J. Piccart

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Emens, L.A., Davidson, N.E. (2009). Postoperative Endocrine Therapy for Invasive Breast Cancer. In: Castiglione, M., Piccart, M. (eds) Adjuvant Therapy for Breast Cancer. Cancer Treatment and Research, vol 151. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-75115-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-75115-3_10

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-75114-6

  • Online ISBN: 978-0-387-75115-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation